DENVILLE, N.J., June 26, 2008 (PRIME NEWSWIRE) -- Lantis Laser Inc. (Pink Sheets:LLSR) (http://www.lantislaser.com), wishes to draw attention to new, recently introduced, clinical recommendations from the American Dental Association Council on Scientific Affairs to assist clinicians in their decision-making process, for the use of composite plastic sealants over very early decay on the occlusal biting surface of teeth in children, adolescents and young adults to stop the disease from progressing.
"Placing sealants on the biting surfaces can stop early decay that is still in the enamel from progressing," pointed out Dr. Craig Gimbel, Executive Vice President of Clinical Affairs for Lantis Laser. "This article mentions that the clinician may be uncomfortable to make the decision to place a sealant because of unavailable adequate diagnostic tools for diagnosis and monitoring to ascertain if the sealant will be placed on top of existing decay in the enamel."
Dr. Gimbel went on to emphasize that, "Presently, the only accepted way to ascertain if decay is present is by recognition of tooth surface color changes, which can be misinterpreted as stains or defects instead of decay or possibly decay when it didn't exist at all." It is well documented that x-rays do not generally have the ability to image very early decay, which is important for the success of this procedure.
It is important to note that the ADA states that clinicians should not obtain radiographs for the sole purpose of placing sealants and should consult the ADA/U.S. Food and Drug Administration guidelines regarding selection criteria for dental radiographs which places limitations due to risk of radiation.
Lantis' OCT (Optical Coherence Tomography) Diagnostic Imaging System(tm) will assist the clinician in making an evidence-based decision to place the sealant because of its ability to image early decay and subsurface enamel changes which is indicative of the demineralization, the first stage in the process of decay.
In addition, it will enable the dentist to monitor the sealed tooth surface area in order to determine that this non surgical method of arresting the decay has been effective. Clinical studies have shown that Lantis' OCT Diagnostic Imaging System(tm) is the only dedicated dental imaging system that can provide evidence for early decay demineralization and then follow the process of remineralizing as the bacteria die under the placed sealant, all without the risk of radiation. The placement of sealants will enable patients to possibly avoid invasive dental procedures, such as fillings, that are associated with later stage decay.
Lantis' OCT Dental Imaging System(tm) is based on novel light-based, bio-medical imaging technology, Optical Coherence Tomography, that enables the dentist to do diagnostic imaging, chairside and in real-time. As the power source is light-based, unlike x-ray there is no harmful radiation. Images can be captured at a resolution of up to 10 times that of x-ray, enabling early detection of decay and detailed examination of microstructural defects.
About Lantis Laser
Lantis was formed to commercialize the application of novel technologies in the dental industry. The criteria for selected products include competitive edge, exclusivity and large market potential. Lantis is currently in Phase 2 and Phase 3 development, moving through beta systems, product development and application for FDA clearance and plans to launch the OCT Dental Imaging System(tm) in the first quarter of 2009. Lantis has exclusive rights to the application of OCT technology in the field of dentistry under its license Agreements with Lawrence Livermore National Laboratory (exclusive); Lightlab Imaging (non-exclusive) and AXSUN (exclusive). To find out more about Lantis Laser (Pink Sheets:LLSR), visit www.lantislaser.com
Safe Harbor: Statements regarding financial matters in this press release other than historical facts are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The company intends that such statements about the Company's future expectations, including future revenues and earnings, technology efficacy and all other forward-looking statements be subject to the safe harbors created thereby. The Company is a development stage company who continues to be dependent upon outside capital to sustain its existence. Since these statements (future operational results and sales) involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results.